SLC4A11 Gene Corneal Endothelial Dystrophy Type 2 NGS Genetic Test
Short Name: CHED2 SLC4A11 NGS Test
Also known as: CHED2 Genetic Test, SLC4A11 Gene Sequencing Test, Congenital Hereditary Endothelial Dystrophy Type 2 Genetic Test, SLC4A11 NGS Panel Test, Corneal Dystrophy Molecular Diagnostic Test
SLC4A11 Gene Corneal Endothelial Dystrophy Type 2 NGS Genetic Test test available at DNA Labs India for ₹20,000. Uses Next-Generation Sequencing (NGS) on Blood or Extracted DNA or One Drop Blood on FTA Card samples. Results in Results are typically available within 3 to 4 weeks from the date of sample receipt at the laboratory. Results are delivered via the online patient portal, email, and WhatsApp.. Free home collection in 300+ cities across India.
🩺 Medically Reviewed By
Dr SULOCHANA HEMCHANDRA HOLLA
Consultant Medical Geneticist · Reg: 8532
Last updated: September 7, 2026
Overview
The purpose of the SLC4A11 Gene Corneal Endothelial Dystrophy Type 2 NGS Genetic Test is to identify pathogenic mutations in the SLC4A11 gene responsible for CHED2. This test enables definitive molecular diagnosis, helps differentiate CHED2 from other hereditary and non-hereditary corneal conditions, supports clinical management and surgical decision-making, and provides essential information for genetic counseling, family planning, carrier screening, and prenatal testing in families affected by this condition. NGS genetic DNA test detecets for variant and mutation detection in SLC4A11 gene for Corneal endothelial dystrophy type 2
- Test Code
- 1491
- CPT Code
- 81479
- ICD Code
- H18.5
- Price
- ₹20,000
- Sample Type
- Blood or Extracted DNA or One Drop Blood on FTA Card
- Result Time
- Results are typically available within 3 to 4 weeks from the date of sample receipt at the laboratory. Results are delivered via the online patient portal, email, and WhatsApp.
- Fasting Required
- No
- Method
- Next-Generation Sequencing (NGS)
Corneal endothelial dystrophy type 2 (CHED2) is a rare genetic disorder that affects the cornea, the transparent outer layer of the eye that covers the iris and pupil. This disorder is caused by mutations in the SLC4A11 gene, which provides instructions for making a protein that helps maintain the health and function of the corneal endothelium, the layer of cells that lines the inside of the cornea.
If you suspect that you or someone you know may have CHED2, getting a genetic DNA test may help confirm the diagnosis and provide valuable information for treatment and management. In this blog, we will discuss the symptoms, diagnosis, and cost of the SLC4A11 gene corneal endothelial dystrophy type 2 NGS genetic DNA test in India.
Symptoms of CHED2
CHED2 is a progressive disorder that typically begins in infancy or early childhood. The symptoms of CHED2 may include:
- Cloudy or hazy cornea
- Reduced vision or blurred vision
- Light sensitivity
- Abnormal eye movements
- Increased risk of corneal infections or ulcers
The severity of these symptoms can vary depending on the age of onset and the extent of corneal damage. In some cases, CHED2 may be asymptomatic and only detected through routine eye exams.
Diagnosis of CHED2
Diagnosing CHED2 involves a comprehensive eye exam, including a visual acuity test, a slit-lamp exam, and a corneal pachymetry test to measure the thickness of the cornea. A genetic DNA test may also be recommended to confirm the diagnosis and identify any specific mutations in the SLC4A11 gene.
The SLC4A11 gene corneal endothelial dystrophy type 2 NGS genetic DNA test is a specialized test that uses next-generation sequencing (NGS) technology to analyze the DNA sequence of the SLC4A11 gene. This test can detect the presence of any mutations in the gene that may be responsible for CHED2.
Cost of SLC4A11 Gene Corneal Endothelial Dystrophy Type 2 NGS Genetic DNA Test in India
The cost of the SLC4A11 gene corneal endothelial dystrophy type 2 NGS genetic DNA test in India may vary depending on the testing facility and the specific type of test used. On average, the cost of this test can range from INR 15,000 to INR 25,000.
It is important to note that this test may not be covered by insurance, and patients should check with their insurance provider before undergoing any genetic testing.
Conclusion
CHED2 is a rare genetic disorder that affects the cornea and can cause vision loss and other eye problems. If you suspect that you or someone you know may have CHED2, getting a genetic DNA test can help confirm the diagnosis and provide valuable information for treatment and management.
The SLC4A11 gene corneal endothelial dystrophy type 2 NGS genetic DNA test is a specialized test that uses next-generation sequencing technology to analyze the DNA sequence of the SLC4A11 gene. The cost of this test may vary, but it can provide valuable information for patients and their healthcare providers.
If you are interested in learning more about the SLC4A11 gene corneal endothelial dystrophy type 2 NGS genetic DNA test, contact DNA Labs India today.
Before getting tested ask for Raw Data, FASTQ, and VCF files along with clinical test report from DNA Testing Lab. DNA Labs India is the Only lab that is transparent and will share Raw Data, FASTQ, and VCF files along with the conclusive clinical report for SLC4A11 Gene Corneal endothelial dystrophy type 2 NGS Genetic DNA Test
Sample Collection
A pre-test genetic counseling session is strongly recommended to discuss the implications of genetic testing, obtain informed consent, and draw a pedigree chart of family members affected with or at risk for SLC4A11 gene mutations. Clinical history of the patient, including age of onset, symptoms, family history, and prior ophthalmological evaluations, should be documented. No fasting is required for this test.
Method: Venipuncture or Finger Prick (FTA Card)
Laboratory Analysis
A trained phlebotomist will collect 3-5 mL of venous blood in an EDTA (lavender-top) vacutainer via standard venipuncture. Alternatively, a single drop of blood may be collected on an FTA card via finger prick. The sample will be labeled, sealed, and transported under ambient room temperature conditions to the testing laboratory.
Report Delivery
The blood sample is processed for DNA extraction followed by next-generation sequencing of the SLC4A11 gene. Results are typically available within 3 to 4 weeks. The comprehensive clinical report, along with raw data files (FASTQ and VCF formats), will be shared with the patient and referring physician through the online portal, email, and WhatsApp.
Timeline: Results are typically available within 3 to 4 weeks from the date of sample receipt at the laboratory. Results are delivered via the online patient portal, email, and WhatsApp.
Patient Instructions
About This Test
Who Should Get This Test
The purpose of the SLC4A11 Gene Corneal Endothelial Dystrophy Type 2 NGS Genetic Test is to identify pathogenic mutations in the SLC4A11 gene responsible for CHED2. This test enables definitive molecular diagnosis, helps differentiate CHED2 from other hereditary and non-hereditary corneal conditions, supports clinical management and surgical decision-making, and provides essential information for genetic counseling, family planning, carrier screening, and prenatal testing in families affected by this condition.
NGS genetic DNA test detecets for variant and mutation detection in SLC4A11 gene for Corneal endothelial dystrophy type 2
How to Prepare
- Collect 3-5 mL venous blood in an EDTA vacutainer (lavender/purple top) via standard venipuncture or apply one drop of blood on an FTA card via finger prick
- Ensure proper patient identification and sample labeling at the time of collection
- Mix the blood gently with EDTA by inverting the tube 8-10 times immediately after collection
- Do not freeze the sample; store and transport at ambient room temperature (15-30°C)
- Ship the sample to DNA Labs India within 48 hours of collection
- Include the completed test requisition form, informed consent, and clinical history documentation
- Free home sample collection is available for online bookings across major cities in India including Mumbai, Delhi, Bangalore, Hyderabad, Chennai, Kolkata, Pune, Ahmedabad, Jaipur, Lucknow, Chandigarh, Kochi, Coimbatore, Bhubaneswar, and many more
Doctor's Notes
Reviewed by Dr SULOCHANA HEMCHANDRA HOLLA — MBBS, MD (Medical Genetics) · Reg. No. 8532
"From a clinical ophthalmology perspective, the SLC4A11 gene test is invaluable for confirming CHED2 in infants and children presenting with bilateral corneal clouding. Early molecular diagnosis allows differentiation of CHED2 from other causes of congenital corneal opacity such as Peter anomaly, sclerocornea, or congenital glaucoma. This distinction is critical for surgical planning, as patients with confirmed CHED2 may benefit from early endothelial keratoplasty or penetrating keratoplasty. Genetic confirmation also enables accurate recurrence risk counseling for families planning future pregnancies."
Last updated: September 7, 2026
Test Parameters & Specifications
Sample Stability
- Clotted blood sample in EDTA tube
- Sample collected in heparin (green top) tube, as heparin interferes with PCR and NGS
- Insufficient sample volume (less than 2 mL for whole blood)
- Leaking, damaged, or unlabeled sample container
- Sample received without proper documentation or informed consent
- Contaminated or hemolyzed sample
Understanding Your Results
Pathogenic Variant Detected (Homozygous)
Confirms the diagnosis of CHED2. Two copies of a pathogenic mutation in SLC4A11 have been identified, consistent with autosomal recessive inheritance. Both parents are expected to be carriers. Genetic counseling for family planning and carrier testing for siblings is recommended.
Pathogenic Variant Detected (Compound Heterozygous)
Confirms the diagnosis of CHED2. Two different pathogenic mutations in SLC4A11 have been identified on opposite alleles. Each parent is expected to carry one of the mutations. Genetic counseling for family members is recommended.
Single Pathogenic or Likely Pathogenic Variant (Heterozygous Carrier)
The individual is a carrier of one pathogenic SLC4A11 variant. While typically asymptomatic, carrier testing of the partner and genetic counseling for reproductive planning is recommended. Further analysis or testing of additional genes may be warranted if clinical suspicion for CHED2 remains high.
Variant of Uncertain Significance (VUS) Detected
A variant in SLC4A11 has been identified but cannot be classified as definitively pathogenic or benign based on current evidence. Clinical correlation with ophthalmological findings and family studies is recommended. Repeat analysis may be warranted as new data becomes available.
No Pathogenic Variant Detected
No disease-causing mutations were identified in the coding region and splice-site junctions of the SLC4A11 gene. This result does not completely exclude CHED2 if large structural variants or deep intronic mutations are present. Clinical correlation is advised, and testing of other genes associated with congenital corneal dystrophies may be considered.
Consult your ophthalmologist or geneticist if your test reveals a pathogenic or likely pathogenic variant in the SLC4A11 gene, if a Variant of Uncertain Significance is detected, or if clinical symptoms persist despite a negative genetic result. Additionally, seek genetic counseling if you are planning a family and are found to be a carrier, or if you need guidance regarding treatment options such as corneal transplantation for an affected child.
Limitations
- ⚠Test may not detect large structural variants, copy number variations, or deep intronic mutations outside the sequenced regions
- ⚠Variants of Uncertain Significance (VUS) may be identified and cannot definitively confirm or exclude disease
- ⚠This test does not predict disease severity, age of onset, or rate of progression
- ⚠Results must be interpreted in conjunction with clinical findings, family history, and ophthalmological examination
- ⚠Regulatory and promoter region variants are not assessed by this test
Risks & Considerations
- ●Minor bruising or discomfort at the venipuncture site
- ●Slight risk of infection at the blood collection puncture site
- ●Fainting or lightheadedness during or after blood draw in sensitive individuals
- ●Psychological distress related to genetic test results, particularly if pathogenic variants are identified
- ●Risk of identifying Variants of Uncertain Significance (VUS) which may cause anxiety without providing definitive answers
Interfering Factors
- ●Contaminated or degraded DNA sample due to improper storage or handling
- ●Recent blood transfusion (within 120 days) may affect genotyping accuracy
- ●Clotted blood samples may reduce DNA yield and quality
- ●Sample mislabeling or improper patient identification
Compare With Similar Tests
| Test | SLC4A11 Gene Corneal Endothelial Dystrophy Type 2 NGS Genetic Test | Sanger Sequencing of SLC4A11 | Clinical Slit-Lamp Examination Only | Corneal Pachymetry | Specular Microscopy |
|---|---|---|---|---|---|
| Comparison | SLC4A11 Gene Corneal Endothelial Dystrophy Type 2 NGS Genetic Test |
Frequently Asked Questions
What is the SLC4A11 Gene Corneal Endothelial Dystrophy Type 2 NGS Genetic Test?
Who should undergo this genetic test?
What sample types are accepted for this test?
How long does it take to receive the test results?
What is the cost of the SLC4A11 CHED2 Genetic Test in India?
Is this genetic test covered by health insurance in India?
What does a positive test result mean?
Can this test be performed on newborns and children?
Is genetic counseling required before taking this test?
What is the difference between CHED1 and CHED2?
Does DNA Labs India provide raw genetic data files with the test report?
Is home sample collection available for this genetic test?
Related Tests
Leber's Hereditary Optic Neuropathy (LHON) Mitochondrial Mutation Detection Test
₹25,000Nx Gen Sequencing: Cataract Test
₹28,665Nx Gen Sequencing: Glaucoma Test
₹28,665Nx Gen Sequencing: Corneal Dystrophy Test
₹28,665Nx Gen Sequencing: Leber Congenital Amaurosis Test
₹28,665Nx Gen Sequencing: Ophthalmoplegia Test
₹28,665Reference Laboratory Services
We serve as a reference laboratory for hospitals and clinics across India. Send samples from your facility with same-day pickup, priority processing, and results delivered through our online portal. Competitive institutional pricing available.
Your Data Privacy
Your medical data is protected under Indian law.
✓ Stored in India: All patient records are stored on servers located in India. No data is transferred outside the country.
✓ DPDP Act Compliant: Under the Digital Personal Data Protection Act 2023, you can request deletion of your records at any time by contacting support.
Book Your Test
Enter your details and we'll connect you within 15 minutes.